MMEDF News and Press, Mind Medicine From 10/23/20

Gold is holding steady at around US$1,900 per ounce, but what is its long-term potential? I spoke this week with Nick Barisheff of BMG Group , who has a US$10,000 price target for gold. That may sound outlandish, but Nick explained that the idea is rooted in a correl...

In the wake of a new public listing that has heightened interest in psychedelics, two executives broke down the importance of this development for the Investing News Network (INN). In September, the psychedelics investment story received a boost thanks to the initial public offeri...

MindMed could be a big player in the psychedelic space with two upcoming catalysts. Two major Phase 2 clinical trials involving LSD. One of which reports Q4 2020 has positive anecdotal evidence. Successful acceptance of the NASDAQ up-listing could serve as another major catalyst f...

Mind Medicine (MMEDF) enters into an agreement with Canaccord Genuity pursuant to which the lead underwriter has agreed to purchase 23.81M units on a bought deal basis. The price will be C$1.05 per unit for gross proceeds of ~C$25M.Underwriters option for additional 3.57 units.Press Rele...

MindMed Announces $25 Million Bought Deal Public Offering Canada NewsWire NEW YORK, Oct. 9, 2020 /THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN ...

FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – October 7, 2020 – Depression, anxiety, post-traumatic stress disorder (PTSD), and other mental illnesses have been prevalent in the US for quite some time, but the coronavirus pandemic h...

U.K.-based COMPASS Pathways' ([[CMPS]] +2.1%) strong U.S. debut (shares up 140% since September 18) is the clearest signal yet that investors are bullish on the prospects of using psychedelics to treat mental health disorders including treatment-resistant depression ((TRD)).Its cand...

MindMed To Provide Funding for Psychedelic Medicine Research Training Program at NYU Langone Health and NYU Grossman School of Medicine NEW YORK, Oct. 5, 2020 /CNW/ -- Mind Medicine (MindMed) Inc. (NEO:MMED) (DE:BGHM) (OTC:MMEDF), the leading psychedelic medicine biot...

Similar to Cannabis, Mushrooms could be the next big investment craze. The current political climate favors psychedelics. Near term catalyst could help this become mainstream. For further details see: Macro Trends Making Mushrooms A Magical Investment

OTC listed Mind Medicine ([[MMEDF]] +5.7%) has collaborated with the University Hospital Basel's Liechti Lab in a study to compare the altered states of consciousness induced by psilocybin, an active ingredient found in species of mushrooms and hallucinogenic drug, Lysergic acid die...